Management of Renal Disease

  • Author: Mohamed G. Atta, MD, MPH (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/14/17 (What's New)

Summary

  • Cobicistat[FDA Cobicistat] and dolutegravir[FDA Dolutegravir] are each associated with serum creatinine increase that does not reflect changes in kidney function
  • Before starting either agent or their combinations, measure creatinine levels at baseline, after approximately 1 month on therapy, with the on-treatment level regarded as patient’s new “baseline” value

Action required